YALE UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1701-10-09
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.yale.edu
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1463 trials with phase data)• Click on a phase to view related trials
SORE Study: Sitz Baths After Urogynecologic Reconstruction
- Conditions
- Pelvic Organ ProlapsePostoperative Pain ManagementGynecologic Surgeries
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Yale University
- Target Recruit Count
- 112
- Registration Number
- NCT07215780
- Locations
- 🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸Greenwich Hospital, Greenwich, Connecticut, United States
🇺🇸Yale-New Haven Hospital, New Haven, Connecticut, United States
Long Term Evaluation of Scapular-inserted Contraceptive Implants
- Conditions
- Contraception
- Interventions
- Drug: Scapular-site insertion of etonogestrel contraceptive implant
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Yale University
- Target Recruit Count
- 62
- Registration Number
- NCT07201402
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Identification of Brain Injury Using Portable MRI
- Conditions
- Cardiac Arrest (CA)Hypoxic-Ischemic Brain Injury
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 60
- Registration Number
- NCT07197918
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
RCT of Cervical Ripening Double Ballon Catheter Prior to Dilation and Evacuation.
- Conditions
- Cervical Preparation Prior to Dilation and Evacuation
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT07200115
- Locations
- 🇺🇸
Yale Family Planning Clinic, New Haven, Connecticut, United States
Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis
- Conditions
- Knee Osteoarthritis
- Interventions
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 84
- Registration Number
- NCT07189585
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 334
- Next
News
Google DeepMind's AI Model Discovers Novel Cancer Immunotherapy Approach Through Cell-Level Analysis
Google DeepMind and Yale University unveiled C2S-Scale 27B, a 27-billion-parameter AI foundation model that successfully generated and experimentally validated a novel hypothesis for cancer treatment.
Bexorg Secures $42.5M to Revolutionize CNS Drug Discovery with AI-Powered Whole-Human Brain Platform
Bexorg completed a $23 million Series A financing led by Engine Ventures, bringing total funding to $42.5 million to advance its integrated AI and whole-human brain platform for CNS drug development.
Nilo Therapeutics Emerges from Stealth with $101 Million to Develop Neural Circuit-Based Immunomodulation Therapies
Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases.
Achieve Life Sciences Appoints Dr. Mark Rubinstein as Interim CMO Amid Cytisinicline FDA Review
Achieve Life Sciences has named Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Dr. Cindy Jacobs as the company advances its smoking cessation drug cytisinicline.
Apple Watch Receives FDA Approval for Hypertension Detection Feature, Expected to Identify Over One Million Undiagnosed Cases
Apple's new hypertension notification feature for Apple Watch Series 9 and later models has received FDA approval and will launch with watchOS 26 on September 15.
Early Long COVID Trials of Paxlovid and Monoclonal Antibodies Show No Significant Benefits, But Research Continues
Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.
FDA-Approved Asthma Drug Zileuton Shows Promise in Preventing Food Allergy Reactions
Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.
Failed Long COVID Drug Trial Reveals Critical Study Design Flaws as New Company Plans Restart
Berlin Cures' Phase 2 trial of BC 007 (rovunaptabin) for long COVID failed in November 2024 due to poor patient selection and inadequate outcome measures, despite some participants experiencing dramatic symptom improvements.
Yale Researchers Engineer Novel Antibody-RNA Therapy Platform for Treatment-Resistant Cancers
Yale researchers developed TMAB3, a specially engineered antibody that successfully delivers RNA therapies to treatment-resistant "cold" tumors, significantly reducing tumor size and extending survival in animal models of pancreatic, brain, and skin cancers.
YIV-906 Shows Promising Results in Phase 2b Trial for Advanced Hepatocellular Carcinoma with Hepatitis B
Yiviva's Phase 2b study demonstrated that YIV-906 plus sorafenib significantly improved median overall survival to 14.3 months versus 7.5 months with sorafenib alone in HBV-positive advanced hepatocellular carcinoma patients.